Evergreening and patent cliff hangers – Article from #1 2019
The tragic 9/11 events in 2001 implied a delay in the court proceedings in Boston that dealt[…]
CRISPR/Cas9 system – Article from #1 2019
ABSTRACT The CRISPR/Cas9 discovery has emerged as a powerful technology tool to edit genomes, which allows researchers,[…]
Being equitable about equivalents – Article from #1 2019
Has Lord Neuberger in Actavis [efn_note]Actavis v Eli Lilly [2017] UKSC 48. [/efn_note] introduced “an amorphous general[…]
Second medical use claims – Article from #1 2019
ABSTRACT Second medical use patents and their claims do not only represent highly valuable inventions for both[…]
Do rules experience culture shock – Article from #1 2019
ABSTRACT In order to stimulate product development and innovation in the pharmaceutical industry, the United States Congress[…]
The patentability of Dosage Regimes – Article from #1 2019
ABSTRACT Despite the therapeutical benefits of dosage regimes, being granted and securing patent protection for these types[…]
Safeguarding public health – Article from #1 2019
INTRODUCTION In a world with an estimated population of 7.6 billion, 2 billion people lack access to[…]